KM Research Hub

REVIEW LEDGER

论文复核台

集中查看元数据入排不确定项,以及已识别 KM 但需确认 No. at risk 的内容复核项。

论文元数据入排图像/No. at risk 复核依据
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.PMID 41184595 · 2025-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study.PMID 41193116 · 2025-Novneeds_reviewThe trial is eligible for most criteria (oncology, human, randomized, phase 3, drug intervention, original result), but the required primary/key secondary time-to-event efficacy endpoint is not present. The primary endpoint is a response rate, which is a categorical outcome, not time-to-event. The record's deterministic review correctly identified the lack of a time-to-event signal.pending-The trial is eligible for most criteria (oncology, human, randomized, phase 3, drug intervention, original result), but the required primary/key secondary time-to-event efficacy endpoint is not present. The primary endpoint is a response rate, which is a categorical outcome, not time-to-event. The record's deterministic review correctly identified the lack of a time-to-event signal.
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival.PMID 41320342 · 2025-Noveligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Artificial intelligence-powered spatial analysis of tumor microenvironment in patients with non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitor.PMID 41173494 · 2025-Oct-31eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL.PMID 40737596 · 2025-Oct-30eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.PMID 40923797 · 2025-Oct-30eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study.PMID 41163129 · 2025-Oct-29eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.PMID 41052510 · 2025-Oct-25eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.PMID 40802908 · 2025-Oct-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial.PMID 40825164 · 2025-Oct-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Pembrolizumab Plus Chemotherapy Versus Chemotherapy as Perioperative Therapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer: Final Analysis of the Randomized, Phase III KEYNOTE-585 Study.PMID 40829093 · 2025-Oct-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study.PMID 40902136 · 2025-Oct-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
High-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trial.PMID 40499010 · 2025-Oct-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Randomized Phase 3 study of pomalidomide cyclophosphamide dexamethasone versus pomalidomide dexamethasone in relapse or refractory myeloma: an Asian Myeloma Network study (AMN003).PMID 41052983 · 2025-Oct-06eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group.PMID 40485042 · 2025-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Group-based trajectories of health-related quality of life among pediatric patients with high-risk Hodgkin lymphoma.PMID 40700618 · 2025-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Total tumor volume predicts overall survival and response to induction chemotherapy in patients with colorectal cancer liver metastases: An ancillary study of the phase 3 CAIRO5 trial.PMID 40912057 · 2025-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT.PMID 40986647 · 2025-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Gemcitabine and Cisplatin Plus Polymeric Micellar Paclitaxel and Survival in Advanced Biliary Tract Cancer: A Randomized Clinical Trial.PMID 41032300 · 2025-Oct-01eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC.PMID 40222621 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial.PMID 40460988 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node-only Disease.PMID 40467365 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.PMID 40473109 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Adjuvant chemotherapy for stage IA-IIA non-squamous, non-small-cell lung cancer identified as molecular high-risk by a 14-gene expression profile (AIM-HIGH): an international, randomised, phase 3 trial.PMID 40578381 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Population Pharmacokinetic and Exposure-Response Analyses of Ibrutinib Combined With Bendamustine and Rituximab in Patients With Mantle Cell Lymphoma.PMID 40613748 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Does RSClin provide additional information over classic clinico-pathologic scores (PREDICT 2.1, INFLUENCE 2.0, CTS5)?PMID 40633461 · 2025-Octneeds_reviewThe record describes a secondary/prognostic analysis of trial data, not a primary or key secondary report of a drug intervention's time-to-event efficacy outcome (e.g., OS, PFS, DFS with KM/HR). The time-to-event criterion is not met.pending-The record describes a secondary/prognostic analysis of trial data, not a primary or key secondary report of a drug intervention's time-to-event efficacy outcome (e.g., OS, PFS, DFS with KM/HR). The time-to-event criterion is not met.
Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.PMID 40633690 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Results of a Randomized Augmented Intensification Phase in Acute Lymphoblastic Leukemia in Children in Argentina: GATLA 2010 ALL IC Trial.PMID 40635183 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial.PMID 40750932 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma.PMID 40768190 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.PMID 40945523 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations.PMID 40974872 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial.PMID 41038184 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib.PMID 41139117 · 2025-Octeligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
[Preoperative short-course radiotherapy followed by chemotherapy and PD-1 inhibitor administration for locally advanced rectal cancer: the initial results of a randomized controlled clinical trial (STELLAR II)].PMID 40967882 · 2025-Sep-23eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma Enrolled on S1826.PMID 40523203 · 2025-Sep-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Dual Immune Check Point Blockade in MGMT-Unmethylated Newly Diagnosed Glioblastoma: NRG Oncology BN007, a Randomized Phase II/III Clinical Trial.PMID 40779733 · 2025-Sep-20eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Low-Dose Aspirin for PI3K-Altered Localized Colorectal Cancer.PMID 40961426 · 2025-Sep-18needs_reviewAspirin is a generic/OTC drug, not a novel investigational or marketed oncology therapeutic. The explicit inclusion criterion 'drug-containing intervention' is interpreted to require a novel or marketed therapeutic agent under evaluation, not a repurposed, low-cost, non-patented compound like aspirin. Therefore, the drug_intervention criterion is not met.pending-Aspirin is a generic/OTC drug, not a novel investigational or marketed oncology therapeutic. The explicit inclusion criterion 'drug-containing intervention' is interpreted to require a novel or marketed therapeutic agent under evaluation, not a repurposed, low-cost, non-patented compound like aspirin. Therefore, the drug_intervention criterion is not met.
Gut microbiome modulates the outcome in primary central nervous system lymphoma patients undergoing chemotherapy: An ancillary study from the BLOCAGE trial.PMID 40048707 · 2025-Sep-17eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN.PMID 40198878 · 2025-Sep-11eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.PMID 40454705 · 2025-Sep-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.PMID 40700681 · 2025-Sep-10eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study.PMID 40730077 · 2025-Sep-09needs_reviewThe report is an original result from a Phase III randomized trial with a drug intervention for a human oncology condition. However, it is excluded because it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required; its focus is on patient satisfaction, resource utilization, and secondary safety/experience outcomes.pending-The report is an original result from a Phase III randomized trial with a drug intervention for a human oncology condition. However, it is excluded because it does not present a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS) as required; its focus is on patient satisfaction, resource utilization, and secondary safety/experience outcomes.
Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial.PMID 40795521 · 2025-Sep-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO.PMID 40795524 · 2025-Sep-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Outcomes for FOLFIRI plus bevacizumab or cetuximab in patients treated with oxaliplatin-based adjuvant therapy: A combined analysis of FIRE-3 and CALGB/SWOG 80405 (Alliance).PMID 40803104 · 2025-Sep-09eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial.PMID 40569606 · 2025-Sep-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
QuANTUM-First: Clinical Validation of the LeukoStrat Companion Diagnostic for the Selection of Patients With Acute Myeloid Leukemia Harboring FMS-Like Tyrosine Kinase 3-Internal Tandem Duplications for Treatment With Quizartinib.PMID 40892059 · 2025-Sep-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
Covered versus uncovered endoluminal stenting in the acute management of obstructing colorectal cancer in the palliative setting: randomized clinical trial (CReST2).PMID 40966674 · 2025-Sep-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。
Chemoradiotherapy With or Without Simultaneous Integrated Boost for Cervical Cancer With Full-Thickness Stromal Invasion: A Phase 3 Randomized Clinical Trial.PMID 40971156 · 2025-Sep-02eligible原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。needs_review历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。历史记录已识别 KM 曲线,但旧版 Figure 审查未记录 No. at risk 表;需复核正文或补充材料。